Article
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Nature - 9 Jun 2016
Rodrik-Outmezguine Vanessa S, Okaniwa Masanori, Yao Zhan, Novotny Chris J, McWhirter Claire, Banaji Arpitha, Won Helen, Wong Wai, Berger Mike, de Stanchina Elisa, Barratt Derek G, Cosulich Sabina, Klinowska Teresa, Rosen Neal, Shokat Kevan M
Abstract excerpt
Precision medicines exert selective pressure on tumour cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next-generation therapies to treat the evolving cancer. The PIK3CA-AKT-mTOR pathway is one of the most commonly activated pathways in human cancers, which has led to the development of small-molecule inhibitors that target various nodes in the pathway....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.